Shandong Company Profile
✉ Email this page to a colleague
What is the competitive landscape for SHANDONG
SHANDONG has sixteen approved drugs.
There are five US patents protecting SHANDONG drugs. There are two tentative approvals on SHANDONG drugs.
There are twenty-nine patent family members on SHANDONG drugs in fourteen countries and fifty-six supplementary protection certificates in thirteen countries.
Summary for Shandong
| International Patents: | 29 |
| US Patents: | 5 |
| Tradenames: | 14 |
| Ingredients: | 14 |
| NDAs: | 16 |
Drugs and US Patents for Shandong
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shandong Luye | RYKINDO | risperidone | FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 212849-003 | Jan 13, 2023 | RX | Yes | No | 9,446,135 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Shandong Xinhua | IBUPROFEN | ibuprofen | TABLET;ORAL | 207095-001 | May 5, 2017 | OTC | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Shandong Luye | RYKINDO | risperidone | FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 212849-003 | Jan 13, 2023 | RX | Yes | No | 10,406,161 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Shandong Xinhua | IBUPROFEN | ibuprofen | TABLET;ORAL | 207095-002 | Aug 21, 2018 | OTC | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Shandong Luye | RYKINDO | risperidone | FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 212849-004 | Jan 13, 2023 | RX | Yes | No | 9,532,991 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Shandong Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Poland | 3199146 | ⤷ Start Trial |
| China | 104127385 | ⤷ Start Trial |
| South Korea | 20140026481 | ⤷ Start Trial |
| Hong Kong | 1185560 | ⤷ Start Trial |
| Portugal | 2701687 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Shandong Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0720599 | 300688 | Netherlands | ⤷ Start Trial | PRODUCT NAME: EZETIMIBE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, EN ROSUVASTATINE; NATIONAL REGISTRATION NO/DATE: RVG114002-004 20140811; FIRST REGISTRATION: NO 13-9663 - 9665 20140724 |
| 2059246 | 2024C/552 | Belgium | ⤷ Start Trial | PRODUCT NAME: EEN COMBINATIE VAN (A) MACITENTAN OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT HIERVAN EN (B) TADALAFIL OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT HIERVAN; AUTHORISATION NUMBER AND DATE: EU/1/24/1859 20240930 |
| 2101777 | CA 2016 00024 | Denmark | ⤷ Start Trial | PRODUCT NAME: AMBRISENTAN USED IN COMBINATION TREATMENT WITH TADALAFIL; REG. NO/DATE: EU/1/08/451 (001-004) 20151125 |
| 2059246 | 2490043-3 | Sweden | ⤷ Start Trial | PRODUCT NAME: A COMBINATION OF (A) MACITENTAN OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND (B) TADALAFIL OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REG. NO/DATE: EU/1/24/1859 20240930 |
| 2059246 | CA 2024 00050 | Denmark | ⤷ Start Trial | PRODUCT NAME: KOMBINATION AF (A) MACITENTAN ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF OG (B) TADALAFIL ELLER ET FAR-MACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/24/1859 20240930 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
